Camphor

Camphor Biopharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for neurodegenerative diseases. The company's primary focus is on central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). Their lead program, CP-012, is currently in Phase 2 clinical development for Alzheimer's disease, targeting underlying mechanisms of neurodegeneration. Camphor Biopharma utilizes a precision medicine approach to identify specific patient populations most likely to benefit from their candidates. The company maintains operations in both China and the United States to leverage global expertise in drug development.